REGENERON PHARMACEUTICALS, INC.

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Regeneron Says US FDA Accepts for Review its Supplemental BLA for Libtayo in Combination With Chemotherapy

01/19/2022 | 07:54am EDT


© MT Newswires 2022
All news about REGENERON PHARMACEUTICALS, INC.
08:09aRegeneron Pharmaceuticals, Inc. - HIGH SCHOOL SCIENTISTS FROM AROUND THE WORLD WIN NEAR..
AQ
05/13High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at ..
PR
05/13High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at ..
PR
05/10TRANSCRIPT : Regeneron Pharmaceuticals, Inc. Presents at Bank of America 2022 Healthcare C..
CI
05/05RBC Capital Adjusts Regeneron Pharmaceuticals Price Target to $658 From $647, Maintains..
MT
05/04Regeneron's COVID drug sales outside U.S. help revenue beat
RE
05/04GLOBAL MARKETS LIVE : Airbnb, Pandora, Apple, Twitter, Meta...
05/04WALL STREET STOCK EXCHANGE : Finally, it's time for Powell's speech
05/04TRANSCRIPT : Regeneron Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 04, 2022
CI
05/04US Futures Higher Ahead of Fed Funds Rate Announcement, National Employment Report
MT
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 11 824 M - -
Net income 2022 4 040 M - -
Net cash 2022 8 716 M - -
P/E ratio 2022 17,4x
Yield 2022 -
Capitalization 69 552 M 69 552 M -
EV / Sales 2022 5,15x
EV / Sales 2023 4,64x
Nbr of Employees 10 492
Free-Float 81,0%
Chart REGENERON PHARMACEUTICALS, INC.
Duration : Period :
Regeneron Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 645,52 $
Average target price 689,35 $
Spread / Average Target 6,79%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Chairman, Co-President & CEO
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl SVP-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS, INC.2.22%69 552
GILEAD SCIENCES, INC.-14.10%78 232
VERTEX PHARMACEUTICALS12.35%63 100
WUXI APPTEC CO., LTD.-16.67%43 023
BIONTECH SE-38.39%38 601
GENMAB A/S-22.70%18 636